99fbcd52 Da4b 4be2 Bfd8 789c8ffdc7ee
99fbcd52 Da4b 4be2 Bfd8 789c8ffdc7ee
99fbcd52 Da4b 4be2 Bfd8 789c8ffdc7ee
Test Report
Note
1. Estimated GFR (eGFR) calculated using the 2021 CKD-EPI creatinine equation and GFR Category
reported as per KDIGO guideline 2012.
2. eGFR category G1 or G2 does not fulfil the criteria for CKD, in the absence of evidence of kidney
damage
*319551262* Page 1 of 7
.
Test Report
*319551262* Page 2 of 7
.
Test Report
--------------------------------------------------------------------------------------------
| RISK | TREATMENT GOAL | CONSIDER THERAPY |
| CATEGORY |-----------------------------------------|-------------------------------------|
| | LDL CHOLESTEROL | NON HDL CHLOESTEROL| LDL CHOLESTEROL| NON HDL CHLOESTEROL|
| | (LDL-C)(mg/dL) | (NON HDL-C) (mg/dL)| (LDL-C)(mg/dL) | (NON HDL-C) (mg/dL)|
|------------|--------------------|--------------------|----------------|--------------------|
| Extreme | <50 | <80 | | |
| Risk Group |(Optional goal ≤30) |(Optional goal ≤60) | ≥50 | ≥80 |
| Category A | | | | |
|------------|--------------------|--------------------|----------------|--------------------|
| Extreme | | | | |
| Risk Group | ≤30 | ≤60 | >30 | >60 |
| Category A | | | | |
|------------|--------------------|--------------------|----------------|--------------------|
| Very | <50 | <80 | ≥50 | ≥80 |
| High | | | | |
|------------|--------------------|--------------------|----------------|--------------------|
| High | <70 | <100 | ≥70 | ≥100 |
|------------|--------------------|--------------------|----------------|--------------------|
| Moderate | <100 | <130 | ≥100 | ≥130 |
|------------|--------------------|--------------------|----------------|--------------------|
| Low | <100 | <130 | ≥130* | ≥160* |
--------------------------------------------------------------------------------------------
*In low risk patient, consider therapy after an initial non-pharmacological intervention for at
least 3 months
*319551262* Page 3 of 7
.
Test Report
BUN/Creatinine Ratio 15
(Calculated)
Note
1. Estimated GFR (eGFR) calculated using the 2021 CKD-EPI creatinine equation and GFR Category
reported as per KDIGO guideline 2012.
2. eGFR category G1 or G2 does not fulfil the criteria for CKD, in the absence of evidence of kidney
damage
3. The BUN-to-creatinine ratio is used to differentiate prerenal and postrenal azotemia from renal
azotemia. Because of considerable variability, it should be used only as a rough guide. Normally, the
BUN/creatinine ratio is about 10:1
*319551262* Page 4 of 7
.
Test Report
Physical
Chemical
Microscopy
Result Rechecked,
Please Correlate Clinically.
*319551262*
Page 5 of 7
.
Test Report
Result Rechecked
Estimated average glucose (eAG) 289 mg/dL
Interpretation
HbA1c result is suggestive of Diabetes/ Higher than glycemic goal in a known Diabetic patient.
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy,
comorbid conditions, known CVD or advanced microvascular complications, hypoglycaemia unawareness,
and individual patient considerations
Result Rechecked,
Please Correlate Clinically.
------------------------------------------------------------------------------------------
| Reference Group | Non diabetic | At risk | Diagnosing | Therapeutic goals |
| | adults >=18 years | (Prediabetes) | Diabetes | for glycemic control |
| ----------------|-------------------|---------------|-------------|----------------------|
| HbA1c in % | 4.0-5.6 | 5.7-6.4 | >= 6.5 | <7.0 |
------------------------------------------------------------------------------------------
Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered,
particularly when the HbA1C result does not correlate with the patient’s blood glucose levels.
---------------------------------------------------------------------------------
| FACTORS THAT INTERFERE WITH HbA1C | FACTORS THAT AFFECT INTERPRETATION |
| MEASUREMENT | OF HBA1C RESULTS |
|--------------------------------------|------------------------------------------|
| Hemoglobin variants,elevated fetal | Any condition that shortens erythrocyte |
| hemoglobin (HbF) and chemically | survival or decreases mean erythrocyte |
| modified derivatives of hemoglobin | age (e.g.,recovery from acute blood loss,|
| (e.g. carbamylated Hb in patients | hemolytic anemia, HbSS, HbCC, and HbSC) |
| with renal failure) can affect the | will falsely lower HbA1c test results |
| accuracy of HbA1c measurements | regardless of the assay method used.Iron |
| | deficiency anemia is associated with |
| | higher HbA1c |
*319551262* Page 6 of 7
.
Test Report
Dr Aviral Chandra
MD Pathology
Chief of Laboratory
Dr Lal PathLabs Ltd
IMPORTANT INSTRUCTIONS
ŸTest results released pertain to the specimen submitted .ŸAll test results are dependent on the quality of the sample received by the Laboratory .
ŸLaboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .ŸReport
delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted .ŸCertain tests may require further testing at additional cost
for derivation of exact value. Kindly submit request within 72 hours post reporting.ŸTest results may show interlaboratory variations .ŸThe
Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes /claims concerning the test(s) & or results of test(s).ŸTest results are not valid
for medico legal purposes.ŸThis is computer generated medical diagnostic report that has been validated by Authorized Medical
Practitioner/Doctor. ŸThe report does not need physical signature.
(#) Sample drawn from outside source.
If Test results are alarming or unexpected, client is advised to contact the Customer Care immediately for possible remedial action.
Tel: +91-11-49885050,Fax: - +91-11-2788-2134, E-mail: lalpathlabs@lalpathlabs.com
*319551262* Page 7 of 7